Inhibitor eradication and treatment for acquired hemophilia A
M Franchini, D Focosi - Expert Review of Hematology, 2024 - Taylor & Francis
ABSTRACT Introduction Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune
disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In …
disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In …
[HTML][HTML] Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside
N Evangelidis, N Kotsiou, P Evangelidis… - Current Issues in …, 2024 - mdpi.com
Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological
inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events …
inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events …
[HTML][HTML] Navigating challenges in diagnosing acquired hemophilia A: A case report from Syria
O Nayouf, M Laflouf, I Hamdan, I Alghazawi… - Clinical Case …, 2024 - ncbi.nlm.nih.gov
Acquired hemophilia A (AHA) is an uncommon condition that develops due to the presence
of autoantibodies against coagulation factor VIII (FVIII). Among the various coagulation …
of autoantibodies against coagulation factor VIII (FVIII). Among the various coagulation …
Važnost rane dijagnostike i liječenja stečene hemoflije
M Šekerija - 2024 - zir.nsk.hr
Sažetak Stečena hemofilija je rijetki hemostatski poremećaj uzrokovan nastankom
neutralizirajućih autoantitijela (inhibitora) protiv faktora zgrušavanja, najčešće usmjerenih …
neutralizirajućih autoantitijela (inhibitora) protiv faktora zgrušavanja, najčešće usmjerenih …